- Home
- KPRX vs RAYA Comparison
KPRX vs RAYA Comparison
Compare KPRX & RAYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- RAYA
- Stock Information
- Founded
- KPRX 1998
- RAYA 2019
- Country
- KPRX United States
- RAYA China
- Employees
- KPRX N/A
- RAYA N/A
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- RAYA Metal Fabrications
- Sector
- KPRX Health Care
- RAYA Consumer Discretionary
- Exchange
- KPRX Nasdaq
- RAYA Nasdaq
- Market Cap
- KPRX 8.6M
- RAYA 8.1M
- IPO Year
- KPRX N/A
- RAYA 2022
- Fundamental
- Price
- KPRX $2.99
- RAYA $0.13
- Analyst Decision
- KPRX Strong Buy
- RAYA
- Analyst Count
- KPRX 1
- RAYA 0
- Target Price
- KPRX $10.00
- RAYA N/A
- AVG Volume (30 Days)
- KPRX 62.4K
- RAYA 20.6M
- Earning Date
- KPRX 08-08-2025
- RAYA 01-01-0001
- Dividend Yield
- KPRX N/A
- RAYA N/A
- EPS Growth
- KPRX N/A
- RAYA N/A
- EPS
- KPRX N/A
- RAYA N/A
- Revenue
- KPRX $20,000.00
- RAYA $30,300,360.00
- Revenue This Year
- KPRX N/A
- RAYA $20.95
- Revenue Next Year
- KPRX N/A
- RAYA N/A
- P/E Ratio
- KPRX N/A
- RAYA N/A
- Revenue Growth
- KPRX N/A
- RAYA 49.10
- 52 Week Low
- KPRX $2.51
- RAYA $0.10
- 52 Week High
- KPRX $4.80
- RAYA $3.35
- Technical
- Relative Strength Index (RSI)
- KPRX 47.28
- RAYA 26.36
- Support Level
- KPRX $2.96
- RAYA $0.14
- Resistance Level
- KPRX $3.29
- RAYA $0.24
- Average True Range (ATR)
- KPRX 0.15
- RAYA 0.51
- MACD
- KPRX 0.01
- RAYA -0.34
- Stochastic Oscillator
- KPRX 38.78
- RAYA 0.75
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About RAYA Erayak Power Solution Group Inc.
Erayak Power Solution Group Inc engages in manufacturing, research and development, and wholesale and retail of power solution products. Its product portfolio includes sine wave and off-grid inverters, inverter and gasoline generators, battery, and smart chargers, and custom-designed products. It derives the majority revenue from four products namely inverters, chargers, power bank, and gasoline generators. The company generates the majority of its revenue from Inverters. The company geographically operates in China, Australia, Poland, U.K., and Germany. It derives maximum revenue from China.